Head-To-Head Analysis: MariMed (MRMD) and Its Peers

MariMed (OTCMKTS:MRMDGet Rating) is one of 49 public companies in the “Medicinals & botanicals” industry, but how does it contrast to its competitors? We will compare MariMed to related companies based on the strength of its analyst recommendations, dividends, profitability, valuation, institutional ownership, risk and earnings.

Volatility and Risk

MariMed has a beta of 3.27, suggesting that its stock price is 227% more volatile than the S&P 500. Comparatively, MariMed’s competitors have a beta of 1.49, suggesting that their average stock price is 49% more volatile than the S&P 500.

Valuation & Earnings

This table compares MariMed and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
MariMed $121.46 million $7.22 million 31.02
MariMed Competitors $238.91 million -$56.08 million -7.47

MariMed’s competitors have higher revenue, but lower earnings than MariMed. MariMed is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares MariMed and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MariMed 5.70% 20.87% 6.07%
MariMed Competitors 1,049.13% -154.97% 151.76%

Institutional and Insider Ownership

0.3% of MariMed shares are owned by institutional investors. Comparatively, 17.9% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 28.1% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for MariMed and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MariMed 0 0 2 0 3.00
MariMed Competitors 285 692 690 31 2.28

MariMed currently has a consensus target price of $2.25, indicating a potential upside of 262.90%. As a group, “Medicinals & botanicals” companies have a potential upside of 118.61%. Given MariMed’s stronger consensus rating and higher possible upside, analysts clearly believe MariMed is more favorable than its competitors.

Summary

MariMed beats its competitors on 7 of the 13 factors compared.

About MariMed (Get Rating)

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.